Our Thoughts
September 25, 2024
Department of Justice’s September 2024 Update to Evaluation of Corporate Compliance Programs
Ryan Morris, Liz Prinzi, Matthew Chandler, Casey J. Horton, J. Mark Farrar, and Saul B. Helman
April 26, 2024
Top Ten Takeaways from the 2024 Pharmaceutical Compliance Congress
Liz Prinzi, Matthew Chandler, Casey J. Horton, J. Mark Farrar, and Saul B. Helman
April 11, 2024
How User-Friendly and Effective Are Your Written Standards?
Audrey Koi, Steven Klimberg, Liz Prinzi, Matthew Chandler, and Saul B. Helman
April 10, 2024
Taking Stock of the Recent Flurry of Articles Mining Open Payments Data
Matthew Chandler
January 25, 2024
FTC Bans Mobile App Software Developer from Selling Sensitive Data, Requires Data Deletion
Nick Weil and Brian Segobiano
November 30, 2023
10 Key Quotes and Takeaways from the Office of Inspector General’s (OIG) 2023 General Compliance Program Guidance for Boards of Directors
Steven Klimberg, Johna Carufel, Matthew Chandler, and Saul B. Helman
November 20, 2023
10 Key Quotes and Takeaways from the Office of Inspector General’s (OIG) 2023 General Compliance Program Guidance
Steven Klimberg, Liz Prinzi, Mathew Chandler, Casey Horton, J. Mark Farrar, and Saul B. Helman
November 9, 2023
Highlights from the Pharmaceutical Compliance Forum’s 24th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
Steven Klimberg, Johna Carufel, Liz Prinzi, Mathew Chandler, Brian Segobiano, Casey Horton, J. Mark Farrar, and Saul B. Helman
October 19, 2023
A Reminder on Compliance Considerations in Medical Affairs
Liz Prinzi, Liisa Eisenlohr, and Saul B. Helman
October 11, 2023
Hot Topics in the Specialty Pharma/ Biotech Space: Highlights from the Compliance Congress for Specialty Products
Liz Prinzi and Casey Horton
July 26, 2023
Unveiling the Nexus: Exploring Compliance Challenges in Social Media Engagement within the Life Sciences Industry
Steven Klimberg, Christine Longawa, and Saul B. Helman
July 13, 2023
Unveiling the Bittersweet Truth: Cookies, Pixels, and Privacy on the Web
Macie Stratton, Kari Czeszewski, Nick Weil, Brian Segobiano, and Saul B. Helman
July 10, 2023
Preserving Trust and Empowering Change: The Vital Considerations when Selecting an Independent Monitor
Johna Carufel, Christine Longawa, Casey J. Horton, and Saul B. Helman
June 15, 2023
Prescriptions and Persuasion: Analyzing the Purpose, Risks, and Vulnerabilities of Speaker Programs
Johna Carufel, Matthew Chandler, and Saul B. Helman
May 31, 2023
Highlights from the 20th Annual Pharmaceutical Compliance Congress
Liz Prinzi, Matthew Chandler, Casey Horton, J. Mark Farrar and Saul B. Helman
March 28, 2023
A Polite Reminder: Preventing Fraud Before It Occurs by Inspiring a Culture of Compliance and Promoting Compliance Through Compensation
Steven Klimberg, Liz Prinzi, and Saul B. Helman
March 21, 2023
Carrots and Sticks? Updated DOJ Guidance Encourages Organizations to Incentivize “Good Compliance” Through Positive Reinforcement and Disciplinary Measures
Steven Klimberg, Liz Prinzi, and Saul B. Helman
December 8, 2022
Department of Health and Human Services Tracking Technology Guidance
Nicholas Weil and Brian Segobiano
November 8, 2022
Highlights from The Pharmaceutical Compliance Forum’s 23rd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
Steven Klimberg, Johna Carufel, Liz Prinzi, Matthew Chandler, Christine Longawa, Casey Horton, J. Mark Farrar, and Saul B. Helman
October 4, 2022
Prosecutor Panel at Compliance Congress for Specialty Products Shares Perspectives on New Monaco Memo and Other Areas of Focus
Matthew Chandler and Casey Horton